Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.

(PRWeb July 21, 2021)

Read the full story at https://www.prweb.com/releases/catalent_plans_multi_phase_100_million_expansion_of_italian_facility_to_increase_biologics_manufacturing_capabilities_in_europe/prweb18081651.htm